These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21314962)

  • 1. Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial.
    Combs SE; Habermehl D; Ganten T; Schmidt J; Edler L; Burkholder I; Jäkel O; Haberer T; Debus J
    BMC Cancer; 2011 Feb; 11():67. PubMed ID: 21314962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial.
    Combs SE; Burkholder I; Edler L; Rieken S; Habermehl D; Jäkel O; Haberer T; Haselmann R; Unterberg A; Wick W; Debus J
    BMC Cancer; 2010 Oct; 10():533. PubMed ID: 20925951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma - feasibility and clinical response.
    Habermehl D; Debus J; Ganten T; Ganten MK; Bauer J; Brecht IC; Brons S; Haberer T; Haertig M; Jäkel O; Parodi K; Welzel T; Combs SE
    Radiat Oncol; 2013 Mar; 8():59. PubMed ID: 23497349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial.
    Combs SE; Habermehl D; Kieser M; Dreher C; Werner J; Haselmann R; Jäkel O; Jäger D; Büchler MW; Debus J
    BMC Cancer; 2013 Sep; 13():419. PubMed ID: 24034562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial.
    Combs SE; Kieser M; Habermehl D; Weitz J; Jäger D; Fossati P; Orrechia R; Engenhart-Cabillic R; Pötter R; Dosanjh M; Jäkel O; Büchler MW; Debus J
    BMC Cancer; 2012 Apr; 12():137. PubMed ID: 22472035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.
    Combs SE; Kieser M; Rieken S; Habermehl D; Jäkel O; Haberer T; Nikoghosyan A; Haselmann R; Unterberg A; Wick W; Debus J
    BMC Cancer; 2010 Sep; 10():478. PubMed ID: 20819220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial.
    Combs SE; Edler L; Burkholder I; Rieken S; Habermehl D; Jäkel O; Haberer T; Unterberg A; Wick W; Debus J; Haselmann R
    BMC Cancer; 2010 Nov; 10():615. PubMed ID: 21062428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II Trial Evaluating Carbon Ion Radiotherapy for Salvaging Treatment of Locally Recurrent Nasopharyngeal Carcinoma.
    Kong L; Hu J; Guan X; Gao J; Lu R; Lu JJ
    J Cancer; 2016; 7(7):774-83. PubMed ID: 27162535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbon ion radiotherapy of hepatocellular carcinoma provides excellent local control: The prospective phase I PROMETHEUS trial.
    Hoegen-Saßmannshausen P; Naumann P; Hoffmeister-Wittmann P; Ben Harrabi S; Seidensaal K; Weykamp F; Mielke T; Ellerbrock M; Habermehl D; Springfeld C; Dill MT; Longerich T; Schirmacher P; Mehrabi A; Chang DH; Hörner-Rieber J; Jäkel O; Haberer T; Combs SE; Debus J; Herfarth K; Liermann J
    JHEP Rep; 2024 Jun; 6(6):101063. PubMed ID: 38737600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma.
    Shiba S; Shibuya K; Okamoto M; Okazaki S; Komatsu S; Kubota Y; Nakano T; Ohno T
    Radiat Oncol; 2020 Aug; 15(1):195. PubMed ID: 32795340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Charged-particle therapy for hepatocellular carcinoma.
    Skinner HD; Hong TS; Krishnan S
    Semin Radiat Oncol; 2011 Oct; 21(4):278-86. PubMed ID: 21939857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma.
    Kim JW; Seong J; Lee IJ; Woo JY; Han KH
    Oncotarget; 2016 Jun; 7(26):40756-40766. PubMed ID: 27213593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma-the ISAC trial protocol.
    Uhl M; Edler L; Jensen AD; Habl G; Oelmann J; Röder F; Jäckel O; Debus J; Herfarth K
    Radiat Oncol; 2014 Apr; 9():100. PubMed ID: 24774721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials.
    Kasuya G; Kato H; Yasuda S; Tsuji H; Yamada S; Haruyama Y; Kobashi G; Ebner DK; Okada NN; Makishima H; Miyazaki M; Kamada T; Tsujii H;
    Cancer; 2017 Oct; 123(20):3955-3965. PubMed ID: 28662297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relative biological effectiveness for carbon and oxygen ion beams using the raster-scanning technique in hepatocellular carcinoma cell lines.
    Habermehl D; Ilicic K; Dehne S; Rieken S; Orschiedt L; Brons S; Haberer T; Weber KJ; Debus J; Combs SE
    PLoS One; 2014; 9(12):e113591. PubMed ID: 25460352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A feasibility study of high-dose hypofractionated carbon ion radiation therapy using four fractions for localized hepatocellular carcinoma measuring 3 cm or larger.
    Shibuya K; Ohno T; Katoh H; Okamoto M; Shiba S; Koyama Y; Kakizaki S; Shirabe K; Nakano T
    Radiother Oncol; 2019 Mar; 132():230-235. PubMed ID: 30366726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
    Gandhi M; Choo SP; Thng CH; Tan SB; Low AS; Cheow PC; Goh AS; Tay KH; Lo RH; Goh BK; Wong JS; Ng DC; Soo KC; Liew WM; Chow PK;
    BMC Cancer; 2016 Nov; 16(1):856. PubMed ID: 27821083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma.
    Byun HK; Kim C; Seong J
    Clin Mol Hepatol; 2023 Oct; 29(4):945-957. PubMed ID: 37583055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis.
    Kato H; Tsujii H; Miyamoto T; Mizoe JE; Kamada T; Tsuji H; Yamada S; Kandatsu S; Yoshikawa K; Obata T; Ezawa H; Morita S; Tomizawa M; Morimoto N; Fujita J; Ohto M;
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1468-76. PubMed ID: 15275734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.